Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07773532 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Predictive Value of Inflammatory Biomarkers for Mirabegron Response in Women With Overactive Bladder

StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 31 days later Oct 1, 2027 → Nov 1, 2027
See other at-risk trials from Bagcilar Training and Research Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Oct 1, 2026 to Nov 1, 2026
    • Primary completion pushed from Oct 1, 2027 to Nov 1, 2027
    • Eligibility criteria expanded, about 10 words
    • Publications: details revised at 4 of 4 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Overactive bladder (OAB) is associated with systemic chronic inflammation. Indices derived from complete blood count (such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII)) have shown associations with OAB presence. However, whether baseline inflammatory status predicts response to beta-3 adrenergic agonist therapy remains untested. This prospective observational cohort study evaluates the predictive ability of baseline NLR, PLR, and SII for 3-month treatment response to mirabegron 50 mg in women with OAB.
Trial Details
NCT Number NCT07773532
Lead Sponsor Bagcilar Training and Research Hospital
Conditions
(from sponsor)		 Overactive Bladder (OAB)
Related terms Inflammation, Urinary Bladder, Overactive
Enrollment 115 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov